北大医药股份有限公司

Group 1 - The company has revised its Articles of Association, merging similar clauses, deleting redundant ones, and adjusting wording for accuracy, while other provisions remain unchanged [1] - The company has also revised its attachments, renaming the "Rules of Procedure for Shareholders' Meetings" and making corresponding adjustments [1] - The revised Articles of Association and related documents are available on the company's official disclosure platform [1] Group 2 - The board of directors has proposed to the shareholders' meeting to authorize the management to handle the necessary business registration changes related to the revised Articles of Association [2] - The proposal is subject to approval by the shareholders' meeting [3] Group 3 - The company held its 13th meeting of the 11th board of directors on August 20, 2025, with all 8 directors present, complying with relevant regulations [5] - The meeting reviewed and approved the 2025 semi-annual report and profit distribution plan, with unanimous support from the directors [7][9] Group 4 - The profit distribution plan for the first half of 2025 proposes a cash dividend of 0.30 yuan per 10 shares, totaling approximately 17.88 million yuan, based on a total share capital of 595,987,425 shares [7][39] - The plan will be adjusted if the total share capital changes before implementation [7] Group 5 - The board approved a proposal to cooperate with a subsidiary in reducing its registered capital from 300 million yuan to 100 million yuan due to operational difficulties, followed by a liquidation process [11][46] - This decision aims to optimize the company's investment layout and mitigate operational risks [11][52] Group 6 - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board, and will revise the relevant rules accordingly [14][28] - The proposal to amend the Articles of Association and related documents is also subject to shareholder approval [14][30]